RecruitingPhase 2Phase 3NCT06181422
Metformin and Lactoferrin in Sepsis in Icu
Comparative Study to Evaluate the Safety and Possible Efficacy of Metformin Versus Lactoferrin in ICU Patients With
Sponsor
Tanta University
Enrollment
60 participants
Start Date
Apr 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Sepsis is a life-threatening organ dysfunction triggered by an unregulated response of a host to infection. Sepsis is a reason for substantial mortality and morbidity among intensive care unit (ICU) patients. 1 Therefore, the aim of our study is to compare the safety and efficacy of metformin and lactoferrin in ICU patients with sepsis.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria3
- Age more than 18 years old.
- A diagnosis of sepsis according to the latest Sepsis definition.11
- Estimated GFR \>45 ml/minute.
Exclusion Criteria3
- Pregnancy and breast feeding.
- End stage hepatic disease.
- End stage renal disease -
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMetformin
metformin 500 mg
DRUGLactoferrin
lactoferrin 100 mg
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06181422
Related Trials
ICU Combined Assessment of Cardio-Respiratory Exercise
NCT061939802 locations
Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis
NCT0333400620 locations
Smart Discharges for Older Children
NCT076291547 locations
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
NCT0685464020 locations
Sepsis Multiomic Analysis & Risk sTratification in China
NCT075996441 location